RNS Number : 3654P
Medgenics Inc
01 October 2013
|
Press Release
|
1 October 2013
|
Appointment of Nominated Adviser and Joint Broker
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) ("the Company"), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that Oriel Securities Limited has been appointed as the Company's nominated adviser and joint broker with immediate effect.
About Medgenics
Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.
For further information, please contact:
|
Abchurch Communications
Joanne Shears / Jamie Hooper / Harriet Rae
[email protected]
|
+44 207 398 7719
|
|
Oriel Securities (NOMAD & Joint Broker)
Jonathan Senior / Giles Balleny
|
+44 207 776 1200
|
|
SVS Securities plc (Joint Broker)
Alex Brearley
|
+44 207 638 5600
|
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCNKDDKOBDKOKK